Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Target Lowered at Citigroup

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price objective cut by stock analysts at Citigroup from $32.00 to $22.00 in a research note issued on Thursday, Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup‘s target price suggests a potential upside of 41.48% from the stock’s current price.

A number of other research firms also recently issued reports on RARE. HC Wainwright cut their target price on shares of Ultragenyx Pharmaceutical from $50.00 to $25.00 and set a “buy” rating for the company in a research report on Thursday, September 3rd. Guggenheim dropped their price target on shares of Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating on the stock in a research note on Tuesday, August 4th. Cantor Fitzgerald lifted their price objective on Ultragenyx Pharmaceutical from $33.00 to $39.00 and gave the company an “overweight” rating in a research report on Friday, September 18th. The Goldman Sachs Group lowered their target price on Ultragenyx Pharmaceutical from $19.00 to $17.00 and set a “neutral” rating on the stock in a research note on Wednesday. Finally, Bank of America downgraded Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating in a research note on Thursday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $29.79.

Ultragenyx Pharmaceutical Trading Down 9.4%

NASDAQ:RARE traded down $1.61 on Thursday, hitting $15.55. 5,383,217 shares of the company’s stock traded hands, compared to its average volume of 2,885,698. Ultragenyx Pharmaceutical has a 1 year low of $12.73 and a 1 year high of $39.89. The firm has a 50-day moving average price of $16.45 and a 200-day moving average price of $22.78. The company has a market cap of $1.53 billion, a PE ratio of -3.00 and a beta of 0.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported ($1.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.06). The firm had revenue of $173.00 million for the quarter, compared to analyst estimates of $182.49 million. During the same period last year, the business earned ($1.81) earnings per share. Ultragenyx Pharmaceutical’s quarterly revenue was up 8.2% compared to the same quarter last year. On average, research analysts forecast that Ultragenyx Pharmaceutical will post -4.30 EPS for the current fiscal year.

Insider Activity

In other news, CFO Howard Horn sold 7,066 shares of the company’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $15.27, for a total transaction of $107,897.82. Following the completion of the sale, the chief financial officer owned 89,229 shares in the company, valued at approximately $1,362,526.83. This represents a 7.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 8,510 shares of company stock worth $127,561. Corporate insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in Ultragenyx Pharmaceutical during the second quarter valued at approximately $355,746,000. Bank of America Corp DE bought a new position in shares of Ultragenyx Pharmaceutical in the second quarter valued at approximately $38,347,000. Jefferies Financial Group Inc. acquired a new stake in shares of Ultragenyx Pharmaceutical in the second quarter worth $31,040,000. Eagle Health Investments LP acquired a new stake in shares of Ultragenyx Pharmaceutical in the second quarter worth $29,521,000. Finally, Candriam S.C.A. boosted its holdings in shares of Ultragenyx Pharmaceutical by 37.1% during the 1st quarter. Candriam S.C.A. now owns 1,096,182 shares of the biopharmaceutical company’s stock worth $22,965,000 after buying an additional 296,798 shares during the period. Institutional investors own 97.67% of the company’s stock.

Key Headlines Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: The company said two Priority Review Vouchers are under agreement to be sold for a combined $413 million, and it reaffirmed its expectation of profitability in 2027. It also reported FDA approval of GENGLYCOS and FAYUVI. Company results and guidance
• Positive Sentiment: Despite trimming its price target, Barclays maintained an “overweight” rating at $32. Canaccord also retained a “buy” rating after lowering its target to $34, signaling some analysts still see substantial upside. Barclays rating
• Neutral Sentiment: Ultragenyx’s third-quarter revenue rose 8.2% year over year to $173 million, but remained below analyst expectations. Its loss narrowed from the year-ago quarter. Quarterly results
• Negative Sentiment: Results missed estimates: the loss was $1.16 per share versus consensus of $1.10, and revenue was $173 million versus expectations of about $182.5 million. The shortfall may be weighing on sentiment. Q3 earnings report
• Negative Sentiment: The 2027 profitability target relies on major cost reductions, including at least a 50% cut in R&D spending versus 2025. That may support near-term finances but raises concerns about pipeline investment and future growth; an analyst commentary also highlighted limited contributions from newer launches and pipeline setbacks. Analyst commentary on the commercial pivot

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company concentrates on conditions with significant unmet medical needs, including genetic, metabolic and endocrine disorders, and uses biologics, small molecules and gene therapy approaches in its research and development programs.

Ultragenyx’s commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), a therapy for long-chain fatty acid oxidation disorders.